Cogent Biosciences, Inc. (COGT) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -2239.3%, revenue growth 214.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $14.69M |
| Revenue (TTM) | $0.0B |
| Net Margin | -2239.3% |
| Return on Equity | -70.8% |
| Operating Margin (TTM) | -1592.5% |
| Debt / Equity | 0.42 |
| Current Ratio | 13.57 |
| Net Debt / EBITDA | 1.5 |
| Revenue Growth (YoY) | 214.4% |
| EPS Growth (YoY) | -1.9% |
| FCF Growth (YoY) | 42.0% |
| Price / Book | 10.89 |
| Price / Sales | 237.24 |
| FCF Yield | -5.3% |
| Altman Z-Score | 8.95 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
COGT overview · COGT earnings · COGT KPIs · COGT documents · COGT ownership · COGT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.